Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) has, in accordance with the intention announced by the Company through a press release, on June 22, 2026, resolved on a directed issue of a total of 1,120,605 shares (the “Directed Issue”). A number of Nordic, international, institutional and professional investors participated in the Directed Issue, including both new and existing shareholders.Through the Directed Issue, Curasight receives approximately DKK 20 million before transaction costs. The Directed Issue has been carried out pursuant to the authorization from the Company's general meeting to the Board of Directors under article 5.1.2 of the Company’s articles of association. The subscription price in the Directed Issue has been set at DKK 17.80 per share (the “Subscription Price”), through an accelerated bookbuilding procedure carried out by Sedermera Corporate Finance AB (“Sedermera”). Curasight recently reported encouraging interim data from its Phase I uTREAT® study. Following these results, the Company has carried out the Directed Issue to strengthen its working capital and support the continued clinical development of uTRACE® and uTREAT® through the end of H1 2027.In connection with the Directed Issue, the Company has also renegotiated the outstanding loan from Fenja Capital II A/S ("Fenja Capital", the "Lender").

The Directed Issue

The Board of Directors of Curasight has, based on authorization from the general meeting stated in article 5.1.2 of the Company’s articles of association resolved on a directed issue of shares. The Subscription Price in the Directed Issue has been set at DKK 17.80 per share and has been determined through an accelerated bookbuilding procedure carried out by Sedermera. The Subscription Price corresponds to a discount of approximately 10.28 percent in relation to the volume weighted average price (VWAP) of the Company's share on Spotlight Stock Market during the period from and including 2026-05-06 to and including 2026-06-22. A number of Nordic and international investors participated in the Directed Share Issue, including new and existing shareholders.

Prior to the Directed Issue, the Company's Board of Directors has made an overall assessment and carefully considered the possibility of raising capital through a rights issue. The Board of Directors considers that the reasons for deviating from the shareholders’ pre-emption right are (i) that a rights issue would take a significantly longer time to complete and entail a higher risk for a material adverse effect on the share price, (ii) to diversify and strengthen the Company's shareholder base with Nordic, international, institutional and professional investors, and to strengthen the share's liquidity, (iii) carrying out a directed share issue can be made at lower costs and with less complexity than a rights issue and, the Board of Directors has assessed that a rights issue would also entail a risk of not being fully subscribed or necessitate significant underwriting commitments and (iv) to ensure a strong balance sheet. Considering the above, the Board of Directors has assessed that the Directed Issue, with deviation from the shareholders’ pre-emption rights, is the most favorable alternative for Curasight.

By establishing the Subscription Price in the Directed Issue through an accelerated bookbuilding procedure, it is the assessment of the Board of Directors that the Subscription Price has been determined on market terms.

Motives and use of proceeds

Curasight recently reported encouraging interim data from its Phase I uTREAT® study.Following these results, the Company has carried out the Directed Issue to strengthen its working capital and support the continued clinical development of uTRACE® and uTREAT® through the end of H1 2027. The net proceeds from the Directed Issue are intended to be utilized as follows:

The Board of Directors assesses that the net proceeds from the Directed Issue will be sufficient to fund the Company’s operations until the end of H1 2027.

Loan Facility

In connection with the Directed Issue, the Company has renegotiated the outstanding loan facility with Fenja Capital. The loan facility was secured in December 2025 and amounted to DKK 40 million, structured in two tranches. The first tranche of DKK 25 million, structured as a convertible loan, was drawn in connection with the directed share issue completed in December 2025. In March 2026, Fenja Capital converted part of the loan, and as of today, the outstanding amount under the first tranche totals approximately DKK 20.7 million. During Q2 2026, the Company has also drawn the second and final tranche of the facility, amounting to DKK 15 million.Accordingly, the total outstanding loan amounts to approximately DKK 35.7 million (the “Total Outstanding Loan”).

Following the renegotiation, the maturity date for the Total Outstanding Loan from Fenja Capital has been extended from 29 December 2026 to 30 June 2027.

Number of shares, share capital and dilution
Through the Directed Issue, the Company's share capital will increase by DKK 56,030.25, from DKK 2,417,610.20 to DKK 2,473,640.45, through a new issue of 1,120,605 shares, which means that the total number of shares will increase from 48,352,204 shares to 49,472,809 shares and will result in a dilution of approximately 2.27 percent of the capital for existing shareholders who did not participate in the issue.

Advisors

Sedermera Corporate Finance AB acts as Sole Global Coordinator and bookrunner in connection with the Directed Issue. DLA Piper is the Company's legal advisor.

This disclosure contains information that Curasight is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-06-2026 23:11 CET.

Important information

The publication, release or distribution of this press release may be restricted in certain jurisdictions. Recipients of this press release in jurisdictions where this press release has been published or distributed should inform themselves about and observe any such restrictions. This announcement does not constitute an offer to the public, or a solicitation of any offer, to buy or subscribe for any securities of the Company in any jurisdiction. This document has not been approved by any authority in any jurisdiction and does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation"). No prospectus has been or will be prepared in connection with the Directed Issue. In any EEA Member State, this communication is only addressed to and is only directed at "qualified investors" in that Member State within the meaning of the Prospectus Regulation.

The information contained in this press release is for background purposes only and does not purport to be full or complete. No reliance may or should be placed by any person for any purpose on the information contained herein or its accuracy or completeness. Neither the Company nor any of its affiliates, advisors or representatives accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this press release (or whether any information has been omitted). 

The information in this press release may not be announced, published, copied or distributed, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, Belarus, Russia, South Africa or any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations or would require a prospectus, registration or other measures than those required by Danish law.  

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, registration under the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. 

This announcement does not constitute an invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities in any jurisdiction. This press release does not constitute a recommendation for any investor's decision regarding the Directed Issue. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities may go down as well as up and past performance is no guide to future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release.  

Forward-looking statements
This press release contains forward-looking statements that reflect the Company's intentions, beliefs or expectations regarding the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "anticipates", "should", "could" and, in each case, the negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialize or that they are accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements contained in this press release are accurate and any reader of this press release should not place undue reliance on the forward-looking statements contained in this press release. The information, opinions and forward-looking statements expressed or implied herein are made only as of the date of this press release and may be subject to change.

About Curasight

Curasight is a clinical stage radiopharmaceutical company developing a first-in-class uPAR-targeted theranostic system for aggressive solid tumors. Its radioligand therapy uTREAT® is paired with uTRACE® (uPAR PET imaging) using the same ligand for patient selection and confirmation of tumor targeting; uTRACE® has been evaluated in more than 450 patients across eight solid tumor types.

Curasight is also advancing next-generation uPAR-targeting ligands designed for modular alpha- and beta-emitting radionuclide payloads and substantially higher binding affinity, with the aim of supporting expansion into a broader range aggressive solid tumors. Curasight is based in Denmark and listed on the Spotlight Stock Market (ticker: CURAS).

For more information about the Directed Issue, please contact:

Sedermera Corporate Finance AB

Phone: +46 (0)40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

For further information about the Company, please contact:

Ulrich Krasilnikoff, CEO, Curasight A/S

Phone: +45 22 83 01 60

E-mail:uk@curasight.com

www.curasight.com

Läs mer på Cision